ATE183198T1 - Immunogens gegen gonadotropin releasing hormone - Google Patents

Immunogens gegen gonadotropin releasing hormone

Info

Publication number
ATE183198T1
ATE183198T1 AT95909395T AT95909395T ATE183198T1 AT E183198 T1 ATE183198 T1 AT E183198T1 AT 95909395 T AT95909395 T AT 95909395T AT 95909395 T AT95909395 T AT 95909395T AT E183198 T1 ATE183198 T1 AT E183198T1
Authority
AT
Austria
Prior art keywords
gonadotropin releasing
releasing hormones
immunogen against
against gonadotropin
immunogenic compositions
Prior art date
Application number
AT95909395T
Other languages
English (en)
Inventor
Stephen Grimes
Robert Scibienski
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphton Corp filed Critical Aphton Corp
Application granted granted Critical
Publication of ATE183198T1 publication Critical patent/ATE183198T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/854—Glands
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT95909395T 1994-01-27 1995-01-26 Immunogens gegen gonadotropin releasing hormone ATE183198T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/188,223 US5688506A (en) 1994-01-27 1994-01-27 Immunogens against gonadotropin releasing hormone

Publications (1)

Publication Number Publication Date
ATE183198T1 true ATE183198T1 (de) 1999-08-15

Family

ID=22692254

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909395T ATE183198T1 (de) 1994-01-27 1995-01-26 Immunogens gegen gonadotropin releasing hormone

Country Status (10)

Country Link
US (3) US5688506A (de)
EP (1) EP0741744B1 (de)
JP (1) JP3477713B2 (de)
AT (1) ATE183198T1 (de)
AU (1) AU698738B2 (de)
DE (1) DE69511379T2 (de)
DK (1) DK0741744T3 (de)
ES (1) ES2137498T3 (de)
GR (1) GR3031716T3 (de)
WO (1) WO1995020600A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030617A (en) * 1993-01-12 2000-02-29 The Johns Hopkins University School Of Medicine Use of growth differentiation factor-9 (GDF-9) to inhibit oocyte maturation
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
ES2361474T3 (es) * 1996-02-08 2011-06-17 Cancer Advances, Inc. Procedimientos inmunológicos para el tratamiento del cáncer gastrointestinal.
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
HUP0002760A3 (en) 1997-05-12 2003-03-28 Aphton Corp Woodland Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
AUPO776897A0 (en) * 1997-07-09 1997-07-31 Csl Limited A method of achieving production gains in livestock and agents useful for same
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
CA2328501A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Prevention and treatment of hypergastrinemia
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001045670A2 (en) * 1999-12-23 2001-06-28 Aphton Corporation A stable immunogenic composition for frozen storage
JP2003532740A (ja) * 2000-05-05 2003-11-05 アフトン コーポレーション キメラペプチド免疫原
SI2266603T1 (sl) 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumorska cepiva
WO2002053701A2 (en) 2000-12-29 2002-07-11 Vanderbilt University Epididymal lipocalin gene and uses thereof
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US6810583B2 (en) * 2001-08-07 2004-11-02 International Business Machines Corporation Coupling of conductive vias to complex power-signal substructures
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
WO2004004687A2 (en) * 2002-07-03 2004-01-15 Aphton Corporation Liposomal vaccine
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
ATE419008T1 (de) 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2005120552A1 (en) * 2004-06-11 2005-12-22 Ym Biosciences Inc. METHODS AND FORMULATIONS OF GnRH/LEUKOTOXIN CHIMERAS FOR TESTOSTERONE SUPPRESSION
DK1794586T3 (da) 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
EP2433648A3 (de) 2006-10-12 2012-04-04 GlaxoSmithKline Biologicals S.A. Impfstoff mit einem Öl-in-wasser-emulsionshilfsstoff
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
JP5331105B2 (ja) 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
EP2072060A1 (de) 2007-12-18 2009-06-24 Institut Curie Verfahren und Zusammensetzungen zur Herstellung und Verwendung von Toxinkonjugaten
CA2739318A1 (en) 2008-08-07 2010-02-11 Mercia Pharma, Llc Immunotherapeutic compositions for the treatment of alzheimer's disease
CU23739A1 (es) 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
RU2568839C2 (ru) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ и композиция для синхронизации времени осеменения
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2012112691A1 (en) 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
GB201121571D0 (en) 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
CA2886161A1 (en) 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
EP2925339B1 (de) 2012-11-28 2020-04-29 United-AH II, LLC Verfahren zur synchronisierung der befruchtungszeit bei jungsauen
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
EP3443123B1 (de) 2016-04-11 2021-08-11 Board of Regents, The University of Texas System Verfahren und zusammensetzungen zum nachweis der affinität einzelner t-zellrezeptoren und sequenz
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
EP3624841A4 (de) 2017-06-15 2021-01-27 Cancer Advances, Inc., Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
WO2019051149A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
AU2021335334A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Genetically-adjuvanted rna vaccines
EP4048308A1 (de) 2020-12-23 2022-08-31 Infectious Disease Research Institute Solanesolimpfstoffadjuvanzien und verfahren zu deren herstellung
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
US4618598A (en) * 1982-04-12 1986-10-21 Duke University Method of regulating hormone function or release
US4879112A (en) * 1984-02-07 1989-11-07 University Of Saskatchewan Monoclonal antibodies agaisnt GnRH
US4676981A (en) * 1984-02-07 1987-06-30 University Of Saskatchewan Monoclonal antibodies against GnRH
US4608251A (en) * 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
AU5359186A (en) * 1985-01-25 1986-08-13 Population Council, Inc., The Method & product for enhancing circulating antibody response
US4740500A (en) * 1985-01-31 1988-04-26 The Salk Institute For Biological Studies GnRH antagonists VIII
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
CA1239346A (en) * 1985-06-04 1988-07-19 National Institute Of Immunology Birth control vaccine
AU5993186A (en) * 1985-06-04 1987-01-07 Biotechnology Research Partners Limited Autoantigen vaccines
FR2593705B1 (fr) 1986-02-04 1991-07-26 Lafon Labor Composition pour l'interruption de la grossesse comprenant des anticorps monoclonaux reconnaissant l'hormone chorionique gonadotrope ou un peptide de structure analogue, anticorps monoclonaux, procede de production de ces anticorps, hybridomes et procede d'obtention de ces hybridomes
US4795634A (en) * 1986-03-14 1989-01-03 Aphton Corporation Method for contraception by immunization against the zona pellucida
NZ220932A (en) * 1986-07-03 1990-05-28 Victoria State Composition comprising an antigenic substance, such as lhrh, conjugated to at least two different carriers and method of immunological castration and spaying
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
GB8713240D0 (en) * 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
US4975420A (en) * 1987-09-30 1990-12-04 University Of Saskatchewan Agents and procedures for provoking an immune response to GnRH and immuno sterilizing mammals
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
FR2623715B1 (fr) 1987-11-26 1990-12-21 Lafon Labor Structures peptidiques, immunogenes les contenant et leurs applications au controle de la fertilite
IL91462A0 (en) * 1988-08-30 1990-04-29 Applied Research Systems Recombinant fusion proteins and dna encoding for such a protein
US5036047A (en) 1988-09-29 1991-07-30 Pitman-Moore, Inc. Method and composition for preventing conception
US5661126A (en) * 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
DK0380230T3 (da) * 1989-01-24 1995-01-16 Aphton Corp Immunogene sammensætninger mod gastrin-peptider
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
AU5186090A (en) * 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
US5484592A (en) * 1989-03-23 1996-01-16 Stitching Centraal Diergeneeskundig Instituut Peptide, immunogenic composition and vaccine or medicinal preparation: a method of immunising a mammal against LHRH, and a method of improving the meat quality of pigs
NZ235038A (en) * 1989-08-25 1992-09-25 Biotech Australia Pty Ltd Outermembrane lipoprotein (tratp)/lhrh fusion protein and its use in immunological castration or reproductive inhibition
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
DE4003944A1 (de) 1990-02-14 1991-08-22 Gerhard Dr Prinzhaus Synthetisches polypeptid: lh - rh -- klh (konjugat aus luteinisierendem hormon-releasing hormon und dem keyhole limpet haemocyanin
FR2661180B1 (fr) 1990-04-23 1995-04-28 Inst Nat Sante Rech Med (hydroxyproline 9) lhrh, son procede d'obtention et application comme medicament.
US5648340A (en) * 1991-10-31 1997-07-15 Barnea; Eytan R. Gestational agents for controlling cell proliferation
US5324512A (en) * 1990-12-26 1994-06-28 The Population Council [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses
GB9100468D0 (en) * 1991-01-09 1991-02-20 Proteus Molecular Design Improvements in and relating to hormones
NL9100151A (nl) * 1991-01-29 1992-08-17 Instituut Voor Veeteeltkundig Werkwijze voor het volledig c.q. nagenoeg volledig elimineren van de "beregeur" van vlees van opgefokte mannelijke varkens door tijdens het opfokken de mannelijke varkens te immuniseren tegen het gnrh-hormoon.
KR100257214B1 (ko) * 1991-03-01 2000-05-15 데스꼴롱그 티에리 거세되지 않은 수컷가축의 고기의 관능적 품질을 개선하기 위한 방법
AU634379B2 (en) * 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
US5262521A (en) * 1991-06-07 1993-11-16 Sri International Isolated atrial peptide-degrading enzyme and novel compounds useful as inhibitors thereof
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
DE69230855D1 (de) * 1991-07-26 2000-05-04 Commw Scient Ind Res Org System der bereitstellung eines impfstoffes auf peptidbasis, das sein eigenes adjuvans bildet, und seine herstellung
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
WO1993008290A1 (en) 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5723129A (en) 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9207731D0 (en) * 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
WO1994000590A1 (en) * 1992-06-23 1994-01-06 The Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US5557033A (en) * 1992-09-22 1996-09-17 Regents Of The University Of Minnesota Method of increasing egg production in avian species by active immunization against vasoactive intestinal peptide
FR2700855B1 (fr) * 1993-01-28 1995-03-03 Commissariat Energie Atomique Dosage immunométrique d'un antigène ou d'un haptène.
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5508383A (en) * 1994-03-09 1996-04-16 Tap Holdings Inc. Cyclic peptide LHRH antagonists
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
CA2163325A1 (en) * 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
AU7718696A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines
WO1997015316A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone

Also Published As

Publication number Publication date
WO1995020600A1 (en) 1995-08-03
ES2137498T3 (es) 1999-12-16
AU698738B2 (en) 1998-11-05
US5688506A (en) 1997-11-18
EP0741744A1 (de) 1996-11-13
JPH09508391A (ja) 1997-08-26
AU1737195A (en) 1995-08-15
GR3031716T3 (en) 2000-02-29
DE69511379D1 (en) 1999-09-16
DE69511379T2 (de) 1999-11-25
DK0741744T3 (da) 1999-12-06
US6132720A (en) 2000-10-17
JP3477713B2 (ja) 2003-12-10
US6303123B1 (en) 2001-10-16
EP0741744B1 (de) 1999-08-11

Similar Documents

Publication Publication Date Title
ATE183198T1 (de) Immunogens gegen gonadotropin releasing hormone
MX9101784A (es) Formulaciones,metodos y dispositivos anticonceptivos transdermicos
FI963036A0 (fi) Munasarjan estrogeenista riippuvaisten tilojen hoito
DE69620241D1 (de) Gonadotropin releasing hormon- antagonisten
FI955101A0 (fi) Immunogeenisia LHRH-peptidirakenteita ja synteettisiä immunosysteemin yleisstimulaattoreita rokotteita varten
CY1108597T1 (el) Συνθεσεις που περιεχουν παραγοντα συνδεσης υποδοχεα οχ-40 ή νουκλεϊνικο οξυ που κωδικοποιει αυτον και μεθοδοι για αυξηση της αντιγονου-ειδικης ανοσοαποκρισης
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
ATE116993T1 (de) Saponin-hilfsmittel.
DK1042001T3 (da) Anvendelse af mikropartikler kombineret med submikron-(olie-i-vand)-emulsioner
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
DK377084A (da) Hormonpraeparat til behandling af menopausale forstyrrelser
DE59610600D1 (de) Kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen
DK0914114T3 (da) Fremgangsmåder til behandling af type I-hypersensitivitet under anvendelse af monophosphoryl-lipid A
DE69110877D1 (de) Idiotypen-impfung gegen b-zell-lymphoma.
DK0588578T3 (da) Immunogener
IT1149971B (it) Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
BG103141A (en) Composition of a malaria vaccine
NO20005145L (no) FremgangsmÕte for behandling av fertilitetsproblemer
SE9604581D0 (sv) An agent against cancer and virus infections
EP0282343A3 (de) Verfahren zur Stimulierung der Immunreponsibilität zu bestimmten Antigenen
DK0831881T3 (da) CETP til forøgelse af HDL-cholesterolniveau
DE69827017D1 (de) Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
SE8503975D0 (sv) Hopskjutbar bastu
FR2550945B1 (fr) Compositions d'endotoxines purifiees et leur application pharmacologique
DE69322960D1 (de) Empfängnisverhütender impfstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee